3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Endocrine
1
Conditions
Endometrial Neoplasms
10
Uterine Cervical Neoplasms
5
Ovarian Neoplasms
5
Neoplasm Metastasis
5
Pancreatic Neoplasms
4
Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Neoplasms
3
Triple Negative Breast Neoplasms
2
Rectal Neoplasms
2
Lung Neoplasms
2
Locally Advanced Rectal Cancer (LARC)
2
Head and Neck Neoplasms
2
Fallopian Tube Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Neuroendocrine
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Sarcoma
1
Recurrence
1
Rectal Adenocarcinoma with Mismatch-repair Deficient (dMMR)/ Microsatellite Instability-high (MSI-H)
1
Penile Neoplasms
1
Pathologic Complete Response
1
Ovarian Carcinosarcoma
1
Oropharyngeal Neoplasms
1
Neoplasms, Second Primary
1
Mouth Neoplasms
1
Interventions
Mitotane
7
Cisplatin
6
pembrolizumab
5
Etoposide
3
Doxorubicin
3
camrelizumab
2
apatinib
2
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
Cytoreduction Surgical Procedures
2
sodium thiosulfate
1
iodophenyl metomidate
1
fludarabine phosphate
1
dostarlimab
1
cemiplimab
1
cabozantinib
1
cabazitaxel
1
antineoplaston AS 2-1
1
antineoplaston A10
1
Suramin
1
Sunitinib
1
Streptozocin
1
Sorafenib
1
Radiation
1
Paclitaxel
1
Observation
1
Nivolumab
1
Megestrol Acetate
1
Lymph Node Excision
1
Ipilimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Adrenocortical Carcinoma
×
dostarlimab
×
Clear all
NCT06333314
2025-12-02
Pan-MSI-ACSE
UNICANCER
Phase 2
Recruiting
120 enrolled